Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

被引：38

作者：

Vincenzi, Bruno ^{[1
]}

Napolitano, Andrea ^{[1
]}

Zoccoli, Alice ^{[1
]}

Iuliani, Michele ^{[1
]}

Pantano, Francesco ^{[1
]}

Papapietro, Nicola ^{[2
]}

Denaro, Vincenzo ^{[2
]}

Santini, Daniele ^{[1
]}

Tonini, Giuseppe ^{[1
]}

机构：

[1] Campus Bio Med Univ Rome, Dept Med Oncol, Rome, Italy

[2] Campus Bio Med Univ Rome, Dept Orthopaed & Trauma Surg, Rome, Italy

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷

关键词：

Osteonecrosis of the jaw; Bisphosphonates; Vascular endothelial growth factor (VEGF); CANCER-PATIENTS; BEVACIZUMAB;

D O I：

10.1186/1756-8722-5-56

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bisphosphonate treatment. These patients showed a strongest decrease in VEGF circulating levels at day 7 and at day 21 after the first administration. These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker.

引用

页数：2

共 7 条

[1] Osteonecrosis of the jaw related to bevacizumab [J].

Estilo, Cherry L. ;

Fornier, Monica ;

Farooki, Azeez ;

Carlson, Diane ;

Bohle, George, III ;

Huryn, Joseph M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4037-4038

[2] Bevacizumab-associated osteonecrosis of the jaw [J].

Greuter, S. ;

Schmid, F. ;

Ruhstaller, T. ;

Thuerlimann, B. .

ANNALS OF ONCOLOGY, 2008, 19 (12) :2091-U3

[3] Epidemiology and pathogenesis of osteonecrosis of the jaw [J].

Reid, Ian R. ;

Cornish, Jillian .

NATURE REVIEWS RHEUMATOLOGY, 2012, 8 (02) :90-96

[4]

Santini D, 2003, CLIN CANCER RES, V9, P3215

[5]

Santini D, 2003, CLIN CANCER RES, V9, P2893

[6]

Santini D, 2002, CLIN CANCER RES, V8, P1080

[7] Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw [J].

Yin, Guozhu ;

Bai, Yun ;

Luo, En .

MEDICAL HYPOTHESES, 2011, 76 (03) :347-349

← 1 →